Trafalgar International Inc.
OOTC:GCAND1.14
USD
-0.26
(-18.57%)
Trafalgar International Inc.
OTC:GCAND
(OTC Markets)
Recent
price
1.14
P/E
ratio
0.21
div
yld
- -
ROIC.AI
Capital Structure
USD
•
in mil. unless spec.Working Capital
USD
•
in mil. unless spec.Growth Rates
USD
•
in mil. unless spec.Quarterly Revenue
USD
•
in mil. unless spec.Quarterly Earnings Per Share
USD
•
in mil. unless spec.Quarterly Dividends Per Share
USD
•
in mil. unless spec.- Similar Companies
- Business
- Trafalgar International, Inc., an acquisition and business development holding company, focuses on acquiring, developing, and operating assets across the financial services, financial technology, enterprise technology, and intellectual property sectors. The company provides a diversified portfolio of business solutions and technology assets comprising acquisition and corporate development services, identifying, acquiring, and scaling growth-stage target businesses within digital payments, banking software, financial infrastructure, and transaction processing; strategic capital allocation and portfolio management, offering corporate restructuring, governance advisory, operational optimization, and cross-border expansion services to emerging technology enterprises; intellectual property commercialization, managing, incubating, and licensing proprietary software, data architectures, and industrial innovations; and legacy drug delivery technologies, maintaining a proprietary intellectual property portfolio centered on patented Eluting Transmucosal Patch platforms designed for non-invasive, buccal transmucosal delivery of active pharmaceutical and therapeutic ingredients. The company serves corporate enterprises, financial institutions, and commercial partners across the United States and Latin America. Founded in 2014 and headquartered in Miami, Florida, Trafalgar International, Inc. operates as a public platform traded on the OTC Markets under the ticker symbol GCAND. The company was formerly known as The Greater Cannabis Company, Inc. and operated as a biopharmaceutical developer before completing a major corporate reorganization in mid-2026. In June 2026, Trafalgar Asset Management LLC acquired a 96.62 percent majority controlling interest in the company, prompting a comprehensive strategic pivot away from cannabis therapeutics toward financial services and fintech platforms, which was formalized through a corporate name change to Trafalgar International, Inc. in July 2026 and the initiation of strategic review processes to monetize or out-license its legacy transmucosal drug delivery patents.